CL2019000228A1 - Tratamiento conjunto contra tipos de cáncer hematológico. - Google Patents

Tratamiento conjunto contra tipos de cáncer hematológico.

Info

Publication number
CL2019000228A1
CL2019000228A1 CL2019000228A CL2019000228A CL2019000228A1 CL 2019000228 A1 CL2019000228 A1 CL 2019000228A1 CL 2019000228 A CL2019000228 A CL 2019000228A CL 2019000228 A CL2019000228 A CL 2019000228A CL 2019000228 A1 CL2019000228 A1 CL 2019000228A1
Authority
CL
Chile
Prior art keywords
hematological cancer
treatment against
joint treatment
inhibitor
types
Prior art date
Application number
CL2019000228A
Other languages
English (en)
Inventor
Fei Huang
Joshua J Rusbuldt
Aleksandra Rizo
Original Assignee
Geron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Geron Corp filed Critical Geron Corp
Publication of CL2019000228A1 publication Critical patent/CL2019000228A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Control Of Indicators Other Than Cathode Ray Tubes (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Glass Compositions (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UN TRATAMIENTO CONJUNTO CONTRA TIPOS DE CÁNCER HEMATOLÓGICO. MÁS ESPECÍFICAMENTE, UNA COMBINACIÓN DE UN INHIBIDOR DE LA TELOMERASA Y UN INHIBIDOR DE LA BCL-2 ES ÚTIL PARA TRATAR TIPOS DE CÁNCER HEMATOLÓGICO, QUE INCLUYEN LA AML. EN CIERTAS FORMAS DE REALIZACIÓN, EL INHIBIDOR DE LA TELOMERASA ES EL IMETELSTAT O EL SODIO DE IMETELSTAT, Y EL INHIBIDOR DE LA BCL-2 ES EL ABT-199.
CL2019000228A 2016-08-02 2019-01-29 Tratamiento conjunto contra tipos de cáncer hematológico. CL2019000228A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662370018P 2016-08-02 2016-08-02
EP16197293.0A EP3318276A1 (en) 2016-11-04 2016-11-04 Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
US201662422738P 2016-11-16 2016-11-16

Publications (1)

Publication Number Publication Date
CL2019000228A1 true CL2019000228A1 (es) 2019-05-17

Family

ID=57226888

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019000228A CL2019000228A1 (es) 2016-08-02 2019-01-29 Tratamiento conjunto contra tipos de cáncer hematológico.

Country Status (28)

Country Link
US (2) US11278561B2 (es)
EP (3) EP3318276A1 (es)
JP (3) JP7016856B2 (es)
KR (3) KR20250134002A (es)
CN (2) CN109641002B (es)
AU (2) AU2017305950B2 (es)
CA (2) CA3217021A1 (es)
CL (1) CL2019000228A1 (es)
DK (1) DK3493812T3 (es)
ES (1) ES2941462T3 (es)
FI (1) FI3493812T3 (es)
HR (1) HRP20230300T1 (es)
HU (1) HUE061471T2 (es)
IL (2) IL305332A (es)
LT (1) LT3493812T (es)
MA (1) MA45845B1 (es)
MD (1) MD3493812T2 (es)
MX (2) MX395085B (es)
NZ (1) NZ750191A (es)
PL (1) PL3493812T3 (es)
PT (1) PT3493812T (es)
RS (1) RS64074B1 (es)
SG (1) SG11201900883UA (es)
SI (1) SI3493812T1 (es)
SM (1) SMT202300108T1 (es)
UA (1) UA124935C2 (es)
WO (1) WO2018026646A1 (es)
ZA (1) ZA201900939B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
WO2019023667A1 (en) 2017-07-28 2019-01-31 Janssen Biotech, Inc. METHODS OF TREATING MYELODYSPLASTIC SYNDROME
CA3087261A1 (en) 2018-01-10 2019-07-18 Recurium Ip Holdings, Llc Benzamide compounds
EP3887537A4 (en) 2018-11-29 2023-04-12 Geron Corporation METHODS OF TREATMENT OF MYELODYSPLASTIC SYNDROME
WO2020223351A1 (en) * 2019-04-29 2020-11-05 Immunogen, Inc. Therapeutic combinations comprising anti-cd123 immunoconjugates
CN115776909A (zh) * 2020-07-17 2023-03-10 美国杰龙生物医药公司 皮下端粒酶抑制剂组合物及其使用方法
JP2024504367A (ja) * 2021-01-22 2024-01-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア がんを治療及び改善するための方法
TW202320802A (zh) * 2021-07-16 2023-06-01 美商塞萊托藥品股份有限公司 Ｂｃｌ抑制劑之脂質體調配物
EP4463151A4 (en) 2022-01-19 2025-10-01 Univ Northwestern Agents Targeting Telomerase Reverse Transcriptase (TERT) to Treat Cancer and Sensitize Cancer Cells to Genotoxic Therapy
CN114949230B (zh) * 2022-06-13 2024-12-06 厦门大学附属第一医院 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用
CN118593709B (zh) * 2024-05-28 2025-05-23 湖南大学 Fasn抑制剂的新用途、化合物、化合物的新用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776679A (en) 1994-07-07 1998-07-07 Geron Corporation Assays for the DNA component of human telomerase
US5958680A (en) 1994-07-07 1999-09-28 Geron Corporation Mammalian telomerase
US5583016A (en) 1994-07-07 1996-12-10 Geron Corporation Mammalian telomerase
AU767646B2 (en) 1999-09-10 2003-11-20 Geron Corporation Oligonucleotide N3'-P5' thiophosphoramidates: their synthesis and use
SI3342425T1 (sl) 2003-09-09 2020-04-30 Geron Corporation Modificirani oligonukleotidi za inhibicijo telomeraze
WO2006113426A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of telomerase and tubulin activities
WO2006113470A2 (en) 2005-04-15 2006-10-26 Geron Corporation Cancer treatment by combined inhibition of proteasome and telomerase activities
WO2006124904A2 (en) 2005-05-16 2006-11-23 Geron Corporation Cancer treatment by combined inhibition of telomerase and hsp90 activities
PT2101789E (pt) 2006-10-30 2015-03-24 Geron Corp Inibidor de telomerase combinado e gencitabina para o tratamento de cancro
US8785409B2 (en) 2007-01-30 2014-07-22 Geron Corporation Compounds having anti-adhesive effects on cancer cells
EP2134364B1 (en) 2007-03-09 2013-02-13 Geron Corporation Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
PT3330383T (pt) 2008-10-17 2020-05-06 Geron Corp Grn163l para utiliização como inibidor de telomerase no tratamento de cancro
US8772264B2 (en) * 2009-08-04 2014-07-08 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
EP2914263A4 (en) * 2012-11-02 2016-04-27 Pharmacyclics Inc ADJUVANT THERAPY WITH TEC FAMILY KINASE INHIBITOR
EP2925889B1 (en) 2012-11-30 2018-09-05 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
US9200327B2 (en) 2012-11-30 2015-12-01 Geron Corporation Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors
IL280144B2 (en) * 2012-12-07 2025-05-01 Geron Corp Use of telomerase inhibitors to treat bone marrow culture disorders and bone marrow culture tumors
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
WO2014160071A1 (en) * 2013-03-14 2014-10-02 St. Jude Children's Research Hospital Methods and compositions for the treatment of glutamine-addicted cancers
EA030957B1 (ru) * 2013-03-14 2018-10-31 Оникс Терапьютикс, Инк. Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
RS58659B1 (sr) * 2013-11-06 2019-05-31 Mayo Found Medical Education & Res Postupci i materijali za tretiranje hematoloških maligniteta
US11034757B2 (en) * 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US9635050B2 (en) 2014-07-23 2017-04-25 Cisco Technology, Inc. Distributed supervised architecture for traffic segregation under attack
EA201790504A1 (ru) 2014-09-24 2017-09-29 Семм Форшунгсцентрум Фюр Молекуларе Медицин Гмбх Монослой мононуклеарных клеток периферической крови или клеток костного мозга и его применение
EP3318276A1 (en) * 2016-11-04 2018-05-09 Janssen Biotech, Inc. Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers
WO2019023667A1 (en) 2017-07-28 2019-01-31 Janssen Biotech, Inc. METHODS OF TREATING MYELODYSPLASTIC SYNDROME

Also Published As

Publication number Publication date
PL3493812T3 (pl) 2023-05-08
ES2941462T3 (es) 2023-05-23
JP2024166290A (ja) 2024-11-28
US11278561B2 (en) 2022-03-22
EP3493812B1 (en) 2023-01-04
RS64074B1 (sr) 2023-04-28
JP2019523277A (ja) 2019-08-22
MA45845A (fr) 2019-06-12
CA3217021A1 (en) 2018-02-08
CA3032118A1 (en) 2018-02-08
DK3493812T3 (da) 2023-04-11
EP3493812A1 (en) 2019-06-12
LT3493812T (lt) 2023-04-11
CA3032118C (en) 2023-12-12
CN116327954A (zh) 2023-06-27
CN109641002A (zh) 2019-04-16
EP3318276A1 (en) 2018-05-09
EP4218768A1 (en) 2023-08-02
MA45845B1 (fr) 2025-08-29
UA124935C2 (uk) 2021-12-15
KR102515378B1 (ko) 2023-03-29
BR112019002025A2 (pt) 2019-05-14
KR20250134002A (ko) 2025-09-09
US20220168333A1 (en) 2022-06-02
CN109641002B (zh) 2022-10-18
HUE061471T2 (hu) 2023-07-28
SMT202300108T1 (it) 2023-05-12
HRP20230300T1 (hr) 2023-05-12
IL264451B1 (en) 2023-09-01
AU2017305950A1 (en) 2019-02-21
SI3493812T1 (sl) 2023-05-31
AU2023229592A1 (en) 2023-10-05
KR102854375B1 (ko) 2025-09-04
MX2022010466A (es) 2022-09-19
MX395085B (es) 2025-03-24
ZA201900939B (en) 2023-04-26
JP2022145948A (ja) 2022-10-04
SG11201900883UA (en) 2019-02-27
KR20230047206A (ko) 2023-04-06
US20180036336A1 (en) 2018-02-08
NZ750191A (en) 2023-03-31
FI3493812T3 (fi) 2023-04-14
KR20190049708A (ko) 2019-05-09
PT3493812T (pt) 2023-03-30
WO2018026646A1 (en) 2018-02-08
MD3493812T2 (ro) 2023-05-31
JP7016856B2 (ja) 2022-02-07
IL264451B2 (en) 2024-01-01
MX2019001315A (es) 2019-07-01
IL305332A (en) 2023-10-01
IL264451A (en) 2019-02-28
AU2017305950B2 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
MX2019001315A (es) Tratamiento conjunto contra tipos de cancer hematologico.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CO2018013557A2 (es) Composiciones que comprenden cepas bacterianas
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
CL2019003670A1 (es) Composición que comprende manosa oligosacárido y proceso para realizarla y uso de esta.
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
CL2019001996A1 (es) Usos terapéuticos de un polvo de insectos.
MX2018012285A (es) Metodos de tratamiento para enfermedades colestasicas y fibroticas.
MX387658B (es) Métodos para tratar y/o prevenir queratosis actínica.
MX2020003943A (es) Anticuerpo anti-msln y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
MX2021003263A (es) Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer.
CO2021007006A2 (es) Moduladores de la expresión de irf5
MX2021011334A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende
CL2020000586A1 (es) Moduladores de la expresión de enac.
MX387201B (es) Composiciones para el tratamiento contra infecciones.
UY37572A (es) Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer
CL2016000542A1 (es) Composición que comprende hidroxipropil quitosano junto con excipientes y/o adyuvantes farmacéuticamente aceptables; útil en el tratamiento de la onicomicosis.
EA201990175A1 (ru) Комбинированное лечение гематологических онкологических заболеваний
AR109374A1 (es) Composición para el tratamiento de superficies duras
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
MX2015004217A (es) Mezcla medicinal de tridax procumbens y allium sativum para el tratamiento de leishmanisis y tripanosomiasis.